Abstract:Background: Dexmedetomidine (DEX) is a commonly used sedative in the intensive care unit and has demonstrated cardioprotective properties against ischemia-reperfusion injury in preclinical studies. However, the protective effects of early treatment of DEX in patients with acute myocardial infarction (AMI) and its underlying mechanism are still not fully understood. This study aims to investigate the association between early DEX treatment and in-hospital mortality in patients with AMI, and to explore the potential mediating role of white blood cell (WBC) reduction in this relationship. Methods: A retrospective cohort analysis was conducted using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients with AMI were divided into the DEX and non-DEX group, based on whether they received DEX treatment in the early stage of hospitalization. The primary outcome measured was in-hospital mortality. The study evaluated the association between DEX use and in-hospital mortality using the Kaplan-Meier (KM) method and Cox proportional hazards model. Additionally, 1:1 propensity score matching (PSM) was conducted to validate the results. Furthermore, causal mediation analysis (CMA) was utilized to explore potential causal pathways mediated by WBC reduction between early DEX use and the primary outcome. Results: This study analyzed data from 2,781 patients, with 355 in the DEX group and 2,426 in the non-DEX group. KM survival analysis revealed a significantly lower in-hospital mortality rate in the DEX group compared to the non-DEX group. After adjusting for multiple confounding factors, the Cox regression model demonstrated a significant positive impact of DEX on the risk of in-hospital mortality in patients with AMI, with hazard ratios (HR) of 0.50 (95% confidence interval (CI): 0.35-0.71, p < 0.0001). PSM analysis confirmed these results, showing HR of 0.49 (95% CI: 0.31-0.77, p = 0.0022). Additionally, CMA indicated that 13.7% (95% CI: 1.8%-46.9%, p = 0.022) of the beneficial effect of DEX on reducing in-hospital mortality in patients with AMI was mediated by the reduction in WBC. Conclusion: The treatment of DEX was associated with a lower risk of in-hospital mortality in patients with AMI, potentially due to its anti-inflammatory properties.

Dexamethasone Changes the Pharmacokinetics of Amitriptyline and Reduces Its Accumulation in Rat Brain: the Roles of P-gp and Cyp3a2.

Effect of ACEA 1021 on Neurotoxicity Induced by Dexamethasone — Initial Behavioral Study

Dexmedetomidine Maintains Blood-Brain Barrier Integrity by Inhibiting Drp1-related Endothelial Mitochondrial Dysfunction in Ischemic Stroke

Effect of Dexamethasone on Excitatory Amino Acid and Monoamine Neurotransmitter in Cerebral Tissue of Neonatal Rats with Hypoxia-Ischemia

Prevention of central pontine myelinolysis in rats by early treatment with dexamethasone]

Effect of dexamethasone on biliary excretion of bile acids and organic anions in rats

Integrated Profiling Identifies Long-Term Molecular Consequences of Prenatal Dexamethasone Treatment in the Rat Brain—Potential Triggers of Depressive Phenotype and Cognitive Impairment

The neuroprotective effect of dexmedetomidine and its mechanism

Pharmacological mitigation of tissue damage during brain microdialysis

A Mechanism-Based Pharmacokinetic/pharmacodynamic Model for CYP3A1/2 Induction by Dexamethasone in Rats

Effect of P-glycoprotein Inhibitors Erythromycin and Cyclosporin A on Brain Pharmacokinetics of Nimodipine in Rats

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

A Physiologically Based Toxicokinetic Model of P-glycoprotein Transporter-Mediated Placenta Perfusion of Dexamethasone in the Pregnant Rat.

Dexmedetomidine inhibits lipopolysaccharide-in duced inflammatory response in hippocampal astrocytes in vitro

Dexamethasone As A Chemosensitizer for Breast Cancer Chemotherapy: Potentiation of the Antitumor Activity of Adriamycin, Modulation of Cytokine Expression, and Pharmacokinetics

Repurposing of dexpramipexole to treatment of neonatal hypoxic/ischemic encephalopathy

The effect of dexamethasone on excitatory amino acid and C-fos protein in the cerebral tissue of neonatal rat with hypoxia-ischemia

Dexmedetomidine administration is associated with improved outcomes in critically ill patients with acute myocardial infarction partly through its anti-inflammatory activity

DEXMEDETOMIDINE AMELIORATES ACUTE BRAIN INJURY INDUCED BY MYOCARDIAL ISCHEMIA-REPERFUSION VIA UPREGULATING THE HIF-1 PATHWAY

Dexmedetomidine Pretreatment Inhibits Cerebral Ischemia/reperfusion‑induced Neuroinflammation Via Activation of AMPK.

Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice